SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 278 filers reported holding SAGE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,083,000 | -22.8% | 15,000 | +50.0% | 0.40% | -43.2% |
| Q3 2019 | $1,403,000 | -56.2% | 10,000 | -42.9% | 0.71% | -8.6% |
| Q2 2019 | $3,204,000 | +101.4% | 17,500 | +75.0% | 0.78% | +32.3% |
| Q1 2019 | $1,591,000 | +66.1% | 10,000 | 0.0% | 0.59% | +13.6% |
| Q4 2018 | $958,000 | -32.2% | 10,000 | 0.0% | 0.52% | +2.4% |
| Q3 2018 | $1,413,000 | -63.9% | 10,000 | -60.0% | 0.50% | -66.5% |
| Q2 2018 | $3,913,000 | +62.0% | 25,000 | +66.7% | 1.50% | +33.5% |
| Q1 2018 | $2,416,000 | -26.7% | 15,000 | -25.0% | 1.13% | -7.8% |
| Q4 2017 | $3,294,000 | +106.8% | 20,000 | 0.0% | 1.22% | +109.8% |
| Q2 2017 | $1,593,000 | +12.1% | 20,000 | 0.0% | 0.58% | -11.9% |
| Q1 2017 | $1,421,000 | +39.2% | 20,000 | 0.0% | 0.66% | +35.9% |
| Q4 2016 | $1,021,000 | +7.6% | 20,000 | +53.8% | 0.49% | +48.0% |
| Q2 2015 | $949,000 | – | 13,000 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |